In‐Silico Study of Laurus nobilis ‐Derived Silver Nanoparticles for Targeted HER2‐Positive Cancer Therapy

The human epidermal growth factor receptor 2 or HER2 (ErbB2) is a key receptor tyrosine kinase implicated in cancer progression, making it an important therapeutic target. This study evaluated the potential of Laurus nobilis ‐derived bioactive compounds and biogenically synthesized silver nanoparticles (AgNPs) for targeted HER2‐positive cancer therapy. GC–MS analysis of the leaf extract identified 10 major compounds, including phenol, 2‐methoxy‐3‐(2‐propenyl)‐ (49.62%), caryophyllene (7.00%), and germacrene D (1.05%). Molecular docking using AutoDock Vina revealed that desulphosinigrin exhibited the highest HER2‐binding affinity (−5.7 kcal/mol), while other compounds showed moderate interactions, suggesting potential inhibitory effects. AgNPs synthesized with the extract were characterized by UV–vis spectrophotometry (SPR peak at 430 nm) and TEM, revealing uniform spherical nanoparticles with an average particle size of 14 nm. FTIR analysis confirmed the presence of functional groups involved in nanoparticle stabilization. Drug‐likeness and pharmacokinetic profiling indicated favorable gastrointestinal absorption, hydrophobicity, and hydrogen‐bonding capacity, supporting their suitability as therapeutic candidates. Overall, these results demonstrate that Laurus nobilis ‐derived compounds, particularly when integrated with AgNPs, exhibit promising HER2‐targeting potential, providing a basis for further experimental validation in anticancer applications.